Acetylbritannilactone inhibits neointimal hyperplasia after balloon injury of rat artery by suppressing nuclear factor-κB activation

Journal of Pharmacology and Experimental Therapeutics

Volumn 324, Issue 1, 2008, Pages 292-298

  Liu, Bin ^a   Han, Mei ^a   Wen, Jin Kun ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

1 O ACETYLBRITANNILACTONE; ACETYLBRITANNILACTONE; CYCLOOXYGENASE 2; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LACTONE DERIVATIVE; MACROGOL; NITRIC OXIDE SYNTHASE INHIBITOR; PROSTAGLANDIN E2 INHIBITOR; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY INTIMA PROLIFERATION; ARTICLE; BALLOON CATHETER; CELL PROLIFERATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DEGRADATION KINETICS; DRUG MECHANISM; IMMUNOMODULATION; INHIBITION KINETICS; INULA; INULA BRITANNICA; MALE; NONHUMAN; PERCUTANEOUS TRANSLUMINAL ANGIOPLASTY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RESTENOSIS; RISK REDUCTION; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTERIES; CYCLOOXYGENASE 2; DINOPROSTONE; HYPERPLASIA; I-KAPPA B KINASE; LACTONES; MALE; MYOCYTES, SMOOTH MUSCLE; NEOPLASM PROTEINS; NF-KAPPA B; NUCLEOCYTOPLASMIC TRANSPORT PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; TUNICA INTIMA;

EID: 37349120098     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.107.127407     Document Type: Article

References (37)

1. Autieri MV, Yue TL, Ferstein GZ, and Ohlstein E (1995) Antisense oligonucleotides to the p65 subunit of NF-kappaB inhibit human vascular smooth muscle cell adherence and proliferation and prevent neointima formation in rat carotid arteries. Biochem Biophys Res Commun 213:827-836.
2. Barnes PJ and Karin M (1997) Nuclear factor-kappaB, a pivotal transcription factor in chronic inflammatory diseases. N Engl J Med 336:1066-1071.
3. Bennett MR and Schwartz SM (1995) Antisense therapy for angioplasty restenosis: some critical considerations. Circulation 92:1981-1993.
4. Bernier M, Kwon YK, Pandey SK, Zhu TN, Zhao RJ, Maciuk A, He HJ, Decabo R, and Kole S (2006) Binding of manumycin A inhibits IkappaB kinase beta activity. J Biol Chem 281:2551-2561.
5. Birbach A, Gold P, Binder BR, Hofer E, de Martin R, and Schmid JA (2002) Signaling molecules of the NF-kappa B pathway shuttle constitutively between cytoplasm and nucleus. J Biol Chem 277:10842-10851.
6. Boden WE, O'Rourke RA, Teo KK, Hartigan PM, Maron DJ, Kostuk WJ, Knudtson M, Dada M, Casperson P, Harris CL, et al. (2007) Optimal medical therapy with or without PCI for stable coronary disease. N Engl J Med 356:1503-1516.
7. Breuss JM, Cejna M, Bergmeister H, Kadl A, Baumgartl G, Steurer S, Xu Z, Koshelnick Y, Lipp J, De Martin R, et al. (2002) Activation of nuclear factor-kappa B significantly contributes to lumen loss in a rabbit iliac artery balloon angioplasty model. Circulation 105:633-638.
8. Bu DX, Erl W, de Martin R, Hansson GK, and Yan ZQ (2005) IKKbeta-dependent NF-kappaB pathway controls vascular inflammation and intimal hyperplasia. FASEB J 19:1293-1295.
9. Capron L, Jarnet J, Heudes D, Joseph-Monrose D, and Bruneval P (1997) Repeated balloon injury of rat aorta: a model of neointima with attenuated inhibition by heparin. Arterioscler Thromb Vasc Biol 17:1649-1656.
10. Chandrasekar B, Mummidi S, Mahimainathan L, Patel DN, Bailey SR, Imam SZ, Greene WC, and Valente AJ (2006) Interleukin-18-induced human coronary artery smooth muscle cell migration is dependent on NF-kappaB- and AP-1-mediated matrix metalloproteinase-9 expression and is inhibited by atorvastatin. J Biol Chem 281:15099-15109.
11. Chen F and Shi X (2002) NF-kappaB, a pivotal transcription factor in silica-induced diseases. Mol Cell Biochem 234-235:169-176.
12. Chen YL, Hu CS, Lin FY, Chen YH, Sheu LM, Ku HH, Shiao MS, Chen JW, and Lin SJ (2006) Salvianolic acid B attenuates cyclooxygenase-2 expression in vitro in LPS-treated human aortic smooth muscle cells and in vivo in the apolipoprotein-E-deficient mouse aorta. J Cell Biochem 98:618-631.
13. Chen Z, Hagler J, Palombella VJ, Melandri F, Scherer D, Ballard D, and Maniatis T (1995) Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway. Genes Dev 9:1586-1597.
14. Clowes AW, Reidy MA, and Clowes MM (1983) Kinetics of cellular proliferation after arterial injury: I. Smooth muscle growth in the absence of endothelium. Lab Invest 49:327-333.
15. Connolly E, Bouchier-Hayes DJ, Kaye E, Leahy A, Fitzgerald D, and Belton O (2002) Cyclooxygenase isozyme expression and intimal hyperplasia in a rat model of balloon angioplasty. J Pharmacol Exp Ther 300:393-398.
16. Danenberg HD, Welt FG, Walker M 3rd, Seifert P, Toegel GS, and Edelman ER (2002) Systemic inflammation induced by lipopolysaccharide increases neointimal formation after balloon and stent injury in rabbits. Circulation 105:2917-2922.
17. Ghosh S, May MJ, and Kopp EB (1998) NF-kappa B and Rel proteins: evolutionarily conserved mediators of immune responses. Annu Rev Immunol 16:225-260.
18. 2 synthesis in RAW 264.7 macrophages through the inhibition of iNOS and COX-2 gene expression. Life Sci 75:675-684.
19. Hoffmann A, Levchenko A, Scott ML, and Baltimore D (2002) The IkappaB-NF-kappaB signaling module: temporal control and selective gene activation. Science 298:1241-1245.
20. Huxford T, Huang DB, Malek S, and Ghosh G (1998) The crystal structure of the IkappaBalpha/NF-kappaB complex reveals mechanisms of NF-kappaB inactivation. Cell 95:759-770.
21. + exchanger inhibitors. J Pharmacol Exp Ther 321:345-352.
22. Karin M (1999) How NF-kappaB is activated: the role of the IkappaB kinase (IKK) complex. Oncogene 18:6867-6874.
23. Karin M (2005) Inflammation-activated protein kinases as targets for drug development. Proc Am Thorac Soc 2:386-390.
24. Karin M and Ben-Neriah Y (2000) Phosphorylation meets ubiquitination: the control of NF-[kappa]B activity. Annu Rev Immunol 18:621-663.
25. Kitamoto S, Egashira K, and Takeshita A (2003) Stress and vascular responses: anti-inflammatory therapeutic strategy against atherosclerosis and restenosis after coronary intervention. J Pharmacol Sci 91:192-196.
26. Levrand S, Pesse B, Feihl F, Waeber B, Pacher P, Rolli J, Schaller MD, and Liaudet L (2005) Peroxynitrite is a potent inhibitor of NF-κB activation triggered by inflammatory stimuli in cardiac and endothelial cell lines. J Biol Chem 280: 34878-34887.
27. Park SJ, Kim HS, Yang HM, Park KW, Youn SW, Jeon SI, Kim DH, Koo BK, Chae IH, Choi DJ, et al. (2004) Thalidomide as a potent inhibitor of neointimal hyperplasia after balloon injury in rat carotid artery. Arterioscler Thromb Vasc Biol 24:885-891.
28. Rafi MM, Bai NS, Chi-Tang-Ho, Rosen RT, White E, Perez D, and Dipaola RS (2005) A sesquiterpenelactone from Inula britannica induces anti-tumor effects dependent on Bcl-2 phosphorylation. Anticancer Res 25:313-318.
29. Raines EW and Ferri N (2005) Cytokines affecting endothelial and smooth muscle cells in vascular disease. J Lipid Res 46:1081-1092.
30. Raines EW, Garton KJ, and Ferri N (2004) Beyond the endothelium: NF-kappaB regulation of smooth muscle function. Circ Res 94:706-708.
31. Roviezzo F, Tsigkos S, Kotanidou A, Bucci M, Brancaleone V, Cirino G, and Papapetropoulos A (2005) Angiopoietin-2 causes inflammation in vivo by promoting vascular leakage. J Pharmacol Exp Ther 314:738-744.
32. Scherer DC, Brockman JA, Chen Z, Maniatis T, and Ballard DW (1995) Signalinduced degradation of I kappa B alpha requires site-specific ubiquitination. Proc Natl Acad Sci U S A 92:11259-11263.
33. Song QH, Kobayashi T, Hong T, and Cyong JC (2002) Effects of Inula britannica on the production of antibodies and cytokines and on T cell differentiation in C57BL/6 mice immunized by ovalbumin. Am J Chin Med 30:297-305.
34. Tak PP and Firestein GS (2001) NF-kappaB: a key role in inflammatory diseases. J Clin Invest 107:7-11.
35. Tsatsanis C, Androulidaki A, Venihaki M, and Margioris AN (2006) Signalling networks regulating cyclooxygenase-2. Int J Biochem Cell Biol 38:1654-1661.
36. Welt FG and Rogers C (2002) Inflammation and restenosis in the stent era. Arterioscler Thromb Vasc Biol 22:1769-1776.
37. Zeiffer U, Schober A, Lietz M, Liehn EA, Erl W, Emans N, Yan ZQ, and Weber C (2004) Neointimal smooth muscle cells display a proinflammatory phenotype resulting in increased leukocyte recruitment mediated by P-selectin and chemokines. Circ Res 94:776-784.